HLS Therapeutics Valuation
| HLTRF Stock | USD 2.40 0.04 1.64% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. HLS Therapeutics retains a regular Real Value of $2.08 per share. The prevalent price of the firm is $2.4. Our model calculates the value of HLS Therapeutics from analyzing the firm fundamentals such as return on asset of -0.0276, and Return On Equity of -0.14 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that HLS Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of HLS Therapeutics is based on 3 months time horizon. Increasing HLS Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the HLS pink sheet is determined by what a typical buyer is willing to pay for full or partial control of HLS Therapeutics. Since HLS Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HLS Pink Sheet. However, HLS Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.4 | Real 2.08 | Hype 2.4 | Naive 2.3 |
The real value of HLS Pink Sheet, also known as its intrinsic value, is the underlying worth of HLS Therapeutics Company, which is reflected in its stock price. It is based on HLS Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HLS Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HLS Therapeutics helps investors to forecast how HLS pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HLS Therapeutics more accurately as focusing exclusively on HLS Therapeutics' fundamentals will not take into account other important factors: HLS Therapeutics Total Value Analysis
HLS Therapeutics is currently projected to have takeover price of 344.73 M with market capitalization of 231.54 M, debt of 84.13 M, and cash on hands of 21.16 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the HLS Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
344.73 M | 231.54 M | 84.13 M | 21.16 M |
HLS Therapeutics Investor Information
About 64.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. HLS Therapeutics recorded a loss per share of 0.37. The entity last dividend was issued on the 30th of January 2023. Based on the key indicators related to HLS Therapeutics' liquidity, profitability, solvency, and operating efficiency, HLS Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.HLS Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HLS Therapeutics has an asset utilization ratio of 21.75 percent. This implies that the Company is making $0.22 for each dollar of assets. An increasing asset utilization means that HLS Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.HLS Therapeutics Ownership Allocation
HLS Therapeutics has a total of 32.38 Million outstanding shares. Over half of HLS Therapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.HLS Therapeutics Profitability Analysis
The company reported the revenue of 60.01 M. Net Loss for the year was (13.12 M) with profit before overhead, payroll, taxes, and interest of 50.36 M.HLS Therapeutics Past Distributions to stockholders
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates HLS Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in HLS Therapeutics and how it compares across the competition.
About HLS Therapeutics Valuation
The pink sheet valuation mechanism determines HLS Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of HLS Therapeutics. We calculate exposure to HLS Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HLS Therapeutics's related companies.HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. Hls Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 92 people.
8 Steps to conduct HLS Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates HLS Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct HLS Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain HLS Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine HLS Therapeutics' revenue streams: Identify HLS Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research HLS Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish HLS Therapeutics' growth potential: Evaluate HLS Therapeutics' management, business model, and growth potential.
- Determine HLS Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate HLS Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
A single share of HLS Therapeutics represents a small ownership stake in the entity. As a stockholder of HLS, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
HLS Therapeutics Dividends Analysis For Valuation
Please note that HLS Therapeutics has scaled down on payment of dividends at this time.
There are various types of dividends HLS Therapeutics can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of HLS shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from HLS Therapeutics directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When HLS pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of HLS Therapeutics by the value of the dividends paid out.
HLS Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as HLS Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 32.5 M | |
| Forward Price Earnings | 169.4915 | |
| Retained Earnings | -119.9 M |
Complementary Tools for HLS Pink Sheet analysis
When running HLS Therapeutics' price analysis, check to measure HLS Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLS Therapeutics is operating at the current time. Most of HLS Therapeutics' value examination focuses on studying past and present price action to predict the probability of HLS Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLS Therapeutics' price. Additionally, you may evaluate how the addition of HLS Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |